<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03734172</url>
  </required_header>
  <id_info>
    <org_study_id>LMU-IMPH-AIDA-02</org_study_id>
    <nct_id>NCT03734172</nct_id>
  </id_info>
  <brief_title>Rapid and Accurate Diagnosis of Paediatric (RaPaed) TB - An AIDA (Assessment of Innovative Diagnostics and Algorithms for Early and Sensitive Detection of Acute TB) Platform Study</brief_title>
  <acronym>RaPaed-AIDA-TB</acronym>
  <official_title>Rapid and Accurate Diagnosis of Paediatric (RaPaed) TB - An AIDA (Assessment of Innovative Diagnostics and Algorithms for Early and Sensitive Detection of Acute TB) Platform Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Hoelscher</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cape Town Lung Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Nacional de Saúde, Mozambique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Malawi College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Research Center Borstel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Stellenbosch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beckman Coulter, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cepheid</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Otsuka Novel Products GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Foundation for Innovative New Diagnostics, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Medical Research, Tanzania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Christian Medical College, Vellore, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will serve as a platform to evaluate new diagnostics in children suspected to have
      TB, to establish diagnostic performance (sensitivity and specificity) and calculation of
      positive and negative predictive values in a real-life cohort.

      Finally, this study will comprise results of several tests in its database. This will allow
      simulation of diagnostic algorithms, that may be composed of screening (i.e. rule-out) tests
      together with confirmatory tests to maximize sensitivity and specificity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and Specificit of new test candidates; against a clinica/microbiological reference standard case definition</measure>
    <time_frame>6 months</time_frame>
    <description>The case definition has been defined by an NIH-convened expert panel, published in 2012 and updated in 2015 (S. Graham et al.; CID). This definition describes the diagnostic certainty for a child to suffer from TB.
Possible classifications:
Confirmed active tuberculosis
Unconfirmed tuberculosis
Unlikely tuberculosis
This case definition will be made based on the following:
Confirmed active tuberculosis: bacteriological confirmation obtained (TB lab; positive culture AND/OR WHO endorsed PCR).
Unconfirmed tuberculosis: bacteriological confirmation NOT obtained AND at least two of the following:
Symptoms suggestive of TB X-ray suggestive of TB Close exposure to TB Positive response to TB treatment
• Unlikely tuberculosis: defined as bacteriological confirmation NOT obtained AND criteria for &quot;unconfirmed tuberculosis&quot; NOT met</description>
  </primary_outcome>
  <other_outcome>
    <measure>Ability of new tests to measure response to TB treatment, by measuring the change in experimental test readout over time while receiving TB treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of change of new test readout (e.g. antigen detection rates), in children who receive TB treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of children with confirmed TB, and with other diseases, who have acute and chronic lung impairment using spirometry</measure>
    <time_frame>12 months</time_frame>
    <description>Spirometry parameters: forced vital capacity (FVC) in l; forced expiratory volume in 1 second (FEV 1)</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Tuberculosis</condition>
  <condition>Diagnoses Disease</condition>
  <arm_group>
    <arm_group_label>Paediatric diagnostic group</arm_group_label>
    <description>Paediatric diagnostic group</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sample collection</intervention_name>
    <description>Specimen collection</description>
    <arm_group_label>Paediatric diagnostic group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Molecular speciation test; Mycobacterial DNA extraction will be performed centrally on stored
      samples and will be further analysed using classical molecular MTB typing methods
      (genotyping) as well as by next generation sequencing (genome sequencing).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients 14 years old or younger with a suspicion of active TB are eligible for recruitment
        into the study, if they meet the specified inclusion criteria, and none of the exclusion
        criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Consent and Assent (if applicable): signed written consent/assent, or witnessed oral
             consent/assent in the case of illiteracy, before undertaking any study-specific
             activity. The age threshold for child assent requirement will be laid down in each the
             Investigator Site File based on the local Ethics Committee requirement.

             Of the following, either criterion 2), OR criterion 3), or both, have to be met:

          2. Confirmation of TB disease: microbiological confirmation of active TB disease by
             positive smear AND/OR culture AND/OR PCR (e.g. GeneXpert®); e.g. in a non-study health
             facility AND/OR

          3. Signs and Symptoms: suspicion of active TB disease (one or more criteria):

               1. Chest X-ray suggestive of TB: cavity AND/OR hilar/mediastinal lymph node enlarged
                  AND/OR military pattern

               2. Weight loss or failure to thrive within the previous 3 months that, in the
                  investigator's opinion, is not solely due to inadequate feeding; or to another
                  non-TB cause.

               3. Any cough combined with loss of weight

               4. Cough alone: duration of &gt; 14 days

               5. Repeated episodes of fever within 14 days not responding to course of antibiotics
                  AND positive TST or IGRA, (for malaria endemic areas: AND after malaria has been
                  excluded by at least a negative rapid test)*

               6. Signs &amp; symptoms of extrapulmonary TB:

                    -  Enlarged lymph nodes for &gt; 2 weeks, not painful to palpation;

                    -  Gibbus (especially of recent onset)

                    -  Non-painful enlarged joint

                    -  Pleural effusion

                    -  Pericardial effusion

               7. CSF examination findings in line with TB meningitis with at least elevated
                  protein and low glucose (in relation to serum glucose); OR signs and symptoms in
                  line with TB meningitis/CNS TB if lumbar puncture is contraindicated, in the view
                  of the investigator:

        At least one of the following two:

          -  palsy of oculomotoric nerves of recent onset

          -  focal neurological symptoms indicating elevated intracranial pressure OR CNS lesions,
             of recent onset

        AND/OR at least two of the following less specific signs of TB meningitis/CNS TB (for
        malaria endemic areas: AND a negative malaria rapid diagnostic test*):

          -  Lethargy

          -  Convulsion

          -  Meningism (neck stiffness)

          -  Headache (*the requirement of negative MRDT may be dropped in agreement with the
             sponsor during study conduct.)

        Exclusion Criteria:

          1. Critical condition (if study procedures seems like an undue risk to patient's life),
             such as hypovolemic shock or clinically relevant anaemia (tachypnoea, tachycardia)

          2. Body weight is less than 2 kg

          3. Children of 15 years of age or older

          4. Are currently receiving anti-TB drug(s): ideally, eligible patients should not have
             received any anti-TB treatment. In exceptions, up to three daily doses given since
             treatment start before first study blood draw are acceptable for study inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Hoelscher, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, LMU Munich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Heinrich, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, LMU Munich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Norbert Heinrich, MD</last_name>
    <phone>+49 89 440059805</phone>
    <email>aida@lrz.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Olbrich, MD</last_name>
    <phone>+49 89 440059803</phone>
    <email>aida@lrz.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valsan Philip Verghese, M.D.</last_name>
      <phone>+91 4162282588</phone>
      <email>valsan@cmcvellore.ac.in</email>
    </contact>
    <contact_backup>
      <last_name>Joy Sarojini Michael, FRCPath</last_name>
      <phone>+91 4162282588</phone>
      <email>joymichael@cmcvellore.ac.in</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Malawi College of Medicine</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marriott Nliwasa, PhD</last_name>
      <phone>+265 88 8681948</phone>
      <email>mnliwasa@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Robina Semphere</last_name>
      <phone>+265 997204626</phone>
      <email>robinasemphere@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centro de Investigação e Treino em Saúde da Polana Caniço</name>
      <address>
        <city>Maputo</city>
        <zip>PO.BOX 264</zip>
        <country>Mozambique</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celso Khosa, MD</last_name>
      <phone>+258-82-28893130</phone>
      <email>khosacelso@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Denise 0 Banze</last_name>
      <phone>+258-21-82-28893130</phone>
      <email>den.floripes@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nilesh Bhatt, MD, MMED</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Celso Khosa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cape Town Lung Institute (UCTLI)</name>
      <address>
        <city>Cape Town</city>
        <state>Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather J Zar, Professor</last_name>
      <phone>+27 21 6585324</phone>
      <email>heather.zar@uct.ac.za</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NIMR - Mbeya Medical Research Programme</name>
      <address>
        <city>Mbeya</city>
        <zip>P.O. Box 2410</zip>
        <country>Tanzania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nyanda Ntinginya, MD, PhD</last_name>
      <phone>00255 25 250</phone>
      <phone_ext>2239</phone_ext>
    </contact>
    <investigator>
      <last_name>Nyanda E Ntinginya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
    <country>Malawi</country>
    <country>Mozambique</country>
    <country>South Africa</country>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>November 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Michael Hoelscher</investigator_full_name>
    <investigator_title>Prof Dr med / Sponsor Responsible Person</investigator_title>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>Paediatrics</keyword>
  <keyword>Diagnostics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

